Aktis Oncology Inc.

Contributing Author

Recent Articles by Aktis Oncology Inc.

May-21	Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors AKTS +6.38% AKTS GlobeNewswire
May-11	Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026 AKTS +7.99% AKTS GlobeNewswire
May-06	Aktis Oncology to Present at the BofA Securities Health Care Conference AKTS GlobeNewswire
May-04	Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC) AKTS GlobeNewswire
Apr-21	Aktis Oncology Announces Presentation of First Clinical Imaging and Dosimetry Data for AKY-2519 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting AKTS +7.32% AKTS GlobeNewswire
Apr-16	Aktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of Directors AKTS GlobeNewswire
Mar-30	Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results AKTS +8.89% AKTS +8.16% GlobeNewswire
Feb-24	Aktis Oncology to Present at Upcoming March Investor Conferences AKTS GlobeNewswire
Feb-24	Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate AKTS GlobeNewswire
Jan-13	Aktis Oncology Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares AKTS GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)